System for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response
Abstract
The GPRS is any medicine for treating to optimize the medicine for patients for treating and preventing adverse side and method and system. The system for substituted mark or the target-type (comprising a blood concentration of medicine which) and a lower utility model claims a dosage. Due to the substituted mark and percentage of the state, the fact capable of any target. The substituted mark comprises a drug efficacy any measurement. To the drug efficacy of substituted mark, the system of calculate the medicine changing dosage. Otherwise, fixes the system, wherein bottom of the substituted mark of medicine dosage change prospective outcome.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
58 members in 16 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 34859299 | United States of America | A |
Members58
| Document | Office | Kind | |
|---|---|---|---|
| CA2362429A1 | Canada | A1 | |
| WO0102050A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5919800A | Australia | A | |
| US6267116B1 | United States of America | B1 | |
| US2001018919A1 | United States of America | A1 | |
| US2001020475A1 | United States of America | A1 | |
| CA2404517A1 | Canada | A1 | |
| WO0174084A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5121501A | Australia | A | |
| US2001042551A1 | United States of America | A1 | |
| US2001050920A1 | United States of America | A1 | |
| NO20020043D0 | Norway | D0 | |
| NO20020056D0 | Norway | D0 | |
| NO20020056L | Norway | L | |
| WO0102050A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO0174084A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO0174084B1 | World Intellectual Property Organization (WIPO) | B1 | |
| CA2419431A1 | Canada | A1 | |
| WO0219935A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU8486801A | Australia | A | |
| BR0012241A | Brazil | A | |
| EP1191894A2 | European Patent Office (EPO) | A2 | |
| KR20020036790A | Republic of Korea | A | |
| MXPA01013306A | Mexico | A | |
| CN1359276A | China | A | |
| IL147201A0 | Israel | A0 | |
| IL147201D0 | Israel | D0 | |
| TR2001003831T2 | Türkiye | T2 | |
| TR200103831T2 | Türkiye | T2 | |
| WO02082972A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO02082972A9 | World Intellectual Property Organization (WIPO) | A9 | |
| EP1273174A2 | European Patent Office (EPO) | A2 | |
| JP2003503165A | Japan | A | |
| CA2455455A1 | Canada | A1 | |
| WO03011215A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2002322611A1 | Australia | A1 | |
| WO02082972A3 | World Intellectual Property Organization (WIPO) | A3 | |
| IL151950A0 | Israel | A0 | |
| IL151950D0 | Israel | D0 | |
| EP1311202A1 | European Patent Office (EPO) | A1 | |
| US6575169B2 | United States of America | B2 | |
| US6581606B2 | United States of America | B2 | |
| US6581607B2 | United States of America | B2 | |
| WO03011215A3 | World Intellectual Property Organization (WIPO) | A3 | |
| CA2401913A1 | Canada | A1 | |
| NZ521644A | New Zealand | A | |
| EP1191894A4 | European Patent Office (EPO) | A4 | |
| CA2362429C | Canada | C | |
| AU2001251215B2 | Australia | B2 | |
| US6942614B1 | United States of America | B1 | |
| US7100193B2 | United States of America | B2 | |
| EP1311202A4 | European Patent Office (EPO) | A4 | |
| EP1191894B1 | European Patent Office (EPO) | B1 | |
| AT378015TThis record | Austria | T | |
| ATE378015T1 | Austria | T1 | |
| DE60037116D1 | Germany | D1 | |
| DE60037116T2 | Germany | T2 | |
| CA2455455C | Canada | C |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 945223
Titles2
- German
- SYSTEM ZUR BEHANDLUNG EINES PATIENTEN MIT EINEM MEDIKAMENT ZUR OPTIMIERUNG DER THERAPIE UND ZUR VERHINDERUNG EINES NEGATIVEN NEBENEFFEKTES
- English
- A SYSTEM FOR THE TREATMENT OF A PATIENT WITH A MEDICAMENT FOR OPTIMIZING THERAPY AND PREVENTING A NEGATIVE SUB-EFFECT
Classification
- CPC, 1
- A61K49/0004
- IPC, 5
- A61B19 00
- A61J3 00
- A61G12 00
- A61K49 00
- G06F19 00